Zurich-based company Rivia, which develops an AI-driven data engine for clinical trials, has raised €13 million in a Series A round led by Earlybird, with participation from Defiant, to expand its international presence, particularly in the US.
- Founded in 2022 by Erik Scalfaro and Tiago Kieliger, Rivia integrates data from thousands of heterogeneous files across vendors, standardizes formats, and maps them into trial-specific models covering protocols, visits, and endpoints.
- Rivia currently supports 40 clinical trials across Europe and the US, handling data volumes that have grown over 400% in the past decade.
- Its components include Rivia Core, which consolidates fragmented data into a structured foundation; Rivia Detect, which continuously monitors data quality, clusters thousands of issues, and automates corrective actions; and Rivia Spark, which transforms natural language queries into visual analytics for patient cohorts, adverse events, and biomarkers.
- The firm reports that its system can be deployed within 20 to 30 days, enabling AI agents to provide real-time insights and reduce manual effort in clinical operations, safety monitoring, and executive oversight.
Details of the deal
- The €13 million Series A round was led by Earlybird, with Defiant joining alongside existing investors Speedinvest, Amino Collective, and Nina Capital.
"While most VC funding has gone into AI drug discovery, we believe improving the infrastructure of clinical trials may be one of the most powerful ways to increase the chances of success. Rivia is tackling exactly that problem with an exceptional team and product that gives clinical teams back control of their trials. Proud to support them in their Series A," claims Estelle Botbol, Principal at speedinvest.
- Rivia will use the fresh capital to expand its team, advance its AI-based clinical trial platform, and grow its operations in the US, focusing on improving efficiency and data-driven decision-making in complex trials.
